Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia

Leslie A. AndritsosDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; Correspondence[email protected]

Nicole R. GrieselhuberDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Mirela AnghelinaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Kerry A. RogersDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Sameek RoychowdhuryDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Julie W. ReeserDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Cynthia D. TimmersDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Aharon G. FreudDepartment of Pathology, The Ohio State University, Columbus, OH, USA

James S. BlachlyDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

David M. LucasDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Gerard LozanskiDepartment of Pathology, The Ohio State University, Columbus, OH, USA

Jeffrey A. JonesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Katie WilliamsDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Christopher OakesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Dan JonesDepartment of Pathology, The Ohio State University, Columbus, OH, USA

Michael R. GreverDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

show all

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date